8GN.F CESSATECH A/S DK -20
- Market cap
- EUR 19.0M
- P/E
- -
- P/B
- 22.70x
- ROE
- -187.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8GN.F undervalued?
Graham numberThe Graham number of CESSATECH A/S DK -20 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CESSATECH A/S DK -20 fundamental analysis
No fundamental analysis for CESSATECH A/S DK -20 yet.
CESSATECH A/S DK -20 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CESSATECH A/S DK -20
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of…
Full company profileCESSATECH A/S DK -20 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CESSATECH A/S DK -20 annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 2.49M | 5.72M | 0.00 |
| Operating Income | -13.8M | -17.6M | -22.5M | -19.1M | -15.0M | -14.5M |
| EBITDA | - | -17.6M | -22.5M | -19.1M | -15.0M | -14.5M |
| Net Income | -11.6M | -14.7M | -26.5M | -14.7M | -10.9M | -12.0M |
| EPS | -1.89 | -1.06 | -1.92 | -0.84 | -0.59 | -0.65 |
| Balance Sheet | ||||||
| Total Assets | 30.7M | 28.2M | 8.50M | 15.9M | 13.4M | 8.33M |
| Total Liabilities | 4.41M | 4.33M | 10.4M | 7.63M | 1.23M | 1.94M |
| Shareholders' Equity | 26.2M | 23.9M | -1.92M | 8.27M | 12.2M | 6.39M |
| Cash & Short-term Investments | 3.28M | 23.3M | 3.37M | 12.4M | 8.59M | 2.35M |
| Cash Flow | ||||||
| Operating Cash Flow | -10.1M | -14.8M | -20.0M | -7.21M | -17.6M | -12.5M |
| Capital Expenditure | 127K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -10.2M | -14.8M | -20.0M | -7.21M | -17.6M | -12.5M |
| Ratios | ||||||
| ROE | -44.1% | -61.4% | - | -177.3% | -89.7% | -187.7% |
| ROA | -37.7% | -52.0% | -311.9% | -92.3% | -81.4% | -144.1% |
| Net Profit Margin | - | - | - | -590.1% | -190.7% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CESSATECH A/S DK -20 dividends
CESSATECH A/S DK -20 has not paid dividends in the last 5 fiscal years.
Who owns CESSATECH A/S DK -20
- Insiders 9.54%
- Institutions 0.00%
- Public & others 90.46%
- Shares outstanding 18.6M
- Free float 16.9M
CESSATECH A/S DK -20 company profile
- Company name
- CESSATECH A/S DK -20
- Ticker
- 8GN.F
- ISIN
- DK0061411964
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- Strandvejen 60, Copenhagen, Denmark, 2900
- Phone
- 45 93 87 23 09
- Website
- cessatech.com
About CESSATECH A/S DK -20
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.
CESSATECH A/S DK -20 management
3- Mr. Jes TrygvedChief Executive Officer · born 1973
- Ms. Sarah Margaux Toft JorgensenSenior Director of Finance & Investor Relations
- Mr. Martin JuhlChief Scientific Officer and Head of CMC, Device Development & Operations